AA
VRDN icon

ALPS Advisors’s Viridian Therapeutics VRDN Stock Holding History

ALPS Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.05M Buy
+111,572
New +$1.8M 0.01% 513
2025
Q4 		– Sell
-39,961
Closed -$862K – 1088
2025
Q3 		$862K Sell
39,961
-4,008
-9% -$72.3K ﹤0.01% 574
2025
Q2 		$615K Sell
43,969
-17,509
-28% -$238K ﹤0.01% 597
2025
Q1 		$829K Sell
61,478
-2,579
-4% -$43.9K ﹤0.01% 515
2024
Q4 		$1.23M Buy
64,057
+17,232
+37% +$375K 0.01% 438
2024
Q3 		$1.07M Sell
46,825
-2,941
-6% -$48.1K 0.01% 478
2024
Q2 		$647K Buy
49,766
+5,490
+12% +$76K ﹤0.01% 543
2024
Q1 		$775K Buy
44,276
+9,422
+27% +$183K 0.01% 541
2023
Q4 		$759K Buy
34,854
+2,592
+8% +$40.9K 0.01% 541
2023
Q3 		$495K Buy
32,262
+555
+2% +$10.6K ﹤0.01% 600
2023
Q2 		$754K Buy
+31,707
New +$813K 0.01% 543
2022
Q4 		– Sell
-20,848
Closed -$428K – 1091
2022
Q3 		$428K Buy
20,848
+4,288
+26% +$77.1K ﹤0.01% 640
2022
Q2 		$192K Buy
+16,560
New +$223K ﹤0.01% 1001

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

ALPS Advisors's VRDN Position: Q2 2026 in Review

ALPS Advisors opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 111,572 shares worth $2.05M. The stake represents 0.01% of the portfolio and ranks #513 among its holdings. This is a return to the name: ALPS Advisors previously reported a position in VRDN as recently as Q3 2025.

ALPS Advisors first reported a position in VRDN in Q2 2022 and has held it in 13 quarters since. 65 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • ALPS Advisors held 111,572 shares of Viridian Therapeutics worth $2.05M as of Q2 2026.
  • Viridian Therapeutics was a new ALPS Advisors position in Q2 2026.
  • Viridian Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #513 holding.
  • ALPS Advisors first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 13 quarters since.
  • 65 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.